Sidewinder Therapeutics

Precision bispecific ADCs for cancer

Series B
Founded 2023
Website

About

Founded in 2023, Sidewinder Therapeutics develops novel bispecific antibody-drug conjugates (ADCs) to improve precision in cancer treatment. Their technology enables targeted delivery of payloads to cancer cells using innovative bispecific antibodies, aiming to increase efficacy and reduce side effects compared to traditional ADCs. They operate a biotech therapeutics business model focused on advancing these candidates into clinical development, supported by significant Series B funding to accelerate pipeline progress.

Products

  • Bispecific Antibody-Drug Conjugates — Novel bispecific ADCs designed for highly targeted delivery of cytotoxic payloads to cancer cells.
    Customer sectors: pharmaceutical companies, biotech firms, academic medical centers

Company Details

Sector Deep Tech
Category Biotech & Therapeutics
Stage Series B
Total Funding $137.0M
Employees 51-200
Last Funded April 8, 2026
Last Round $137.0M

Market research & competitive positioning

Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Sidewinder Therapeutics — available to members.

Create a free account Sign in